News

Regeneron: Rapidly Decreasing Importance Of Eylea
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth
Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
Zacks.com on MSN23h
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...